KLP Kapitalforvaltning AS Acquires Shares of 16,400 Anavex Life Sciences Corp. (NASDAQ:AVXL)

KLP Kapitalforvaltning AS bought a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 16,400 shares of the biotechnology company’s stock, valued at approximately $141,000.

Several other institutional investors have also made changes to their positions in AVXL. Invesco Ltd. lifted its position in shares of Anavex Life Sciences by 2,419.8% in the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company’s stock valued at $6,606,000 after acquiring an additional 590,639 shares in the last quarter. Private Advisor Group LLC raised its stake in Anavex Life Sciences by 617.5% during the 1st quarter. Private Advisor Group LLC now owns 214,725 shares of the biotechnology company’s stock valued at $1,842,000 after purchasing an additional 184,800 shares during the period. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Anavex Life Sciences by 197.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 248,139 shares of the biotechnology company’s stock valued at $2,129,000 after purchasing an additional 164,792 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Anavex Life Sciences in the fourth quarter valued at $1,704,000. Finally, Jump Financial LLC acquired a new stake in shares of Anavex Life Sciences in the fourth quarter worth $1,646,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Stock Performance

Anavex Life Sciences stock opened at $11.30 on Friday. Anavex Life Sciences Corp. has a twelve month low of $4.93 and a twelve month high of $14.44. The firm has a market cap of $965.25 million, a PE ratio of -20.55 and a beta of 0.72. The firm’s 50 day moving average price is $9.65 and its two-hundred day moving average price is $9.15.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the previous year, the firm earned ($0.13) EPS. Equities analysts anticipate that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. D. Boral Capital reissued a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th. HC Wainwright reaffirmed a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.